Correction Open Access
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 6, 2020; 8(21): 5494-5495
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5494
Erratum: Author’s Affiliation Correction. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (World J Clin Cases 2019; Aug 6; 7 (15): 1964-1977)
Akio Kaito, Masanori Tokunaga, Reo Sato, Takahiro Kinoshita, Gastric Surgery Division, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Akio Kaito, Takeshi Kuwata, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Akio Kaito, Kohei Shitara, Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Akio Kaito, Tetsuo Akimoto, Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo 163-8001, Japan
Takeshi Kuwata, Kohei Shitara, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Tetsuo Akimoto, Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
ORCID number: Akio Kaito (0000-0003-0839-5695); Takeshi Kuwata (0000-0003-0044-953X); Masanori Tokunaga (0000-0002-3183-349X); Kohei Shitara (0000-0001-5196-3630); Reo Sato (0000-0002-2841-0728); Tetsuo Akimoto (0000-0003-0881-1345); Takahiro Kinoshita (0000-0001-7365-8733).
Author contributions: Kaito A and Kuwata T contributed equally to this correction; i.e., study concepts, study design; all authors contributed equally to manuscript editing and manuscript review.
Conflict-of-interest statement: Not declared.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Takeshi Kuwata, MD, PhD, Doctor, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwano-ha, Kashiwa 277-8577, Japan. tkuwata@east.ncc.go.jp
Received: July 25, 2020
Peer-review started: July 25, 2020
First decision: September 24, 2020
Revised: September 30, 2020
Accepted: October 20, 2020
Article in press: October 20, 2020
Published online: November 6, 2020
Processing time: 104 Days and 1.7 Hours

Abstract

Correction to " Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor-positive gastric cancer" World J Clin Cases 2019; 7(15): 1964-1977. In this article, one of the affiliation of the first author was lacked. Akio Kaito, the first author, belonged to Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo 163-8001, Japan.

Key Words: Correction

Core Tip: This manuscript is an author's affiliation correction for type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (World J Clin Cases 2019; Aug 6; 7 (15): 1964-1977).
  • Citation: Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. Erratum: Author’s Affiliation Correction. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (World J Clin Cases 2019; Aug 6; 7 (15): 1964-1977). World J Clin Cases 2020; 8(21): 5494-5495
  • URL: https://www.wjgnet.com/2307-8960/full/v8/i21/5494.htm
  • DOI: https://dx.doi.org/10.12998/wjcc.v8.i21.5494
CORRECTION

Correction to: Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor-positive gastric cancer. World J Clin Cases 2019; 7(15): 1964-1977 [PMID: 31423428 DOI: 10.12998/wjcc.v7.i15.1964].

In this article[1], one of the affiliation of the first author was lacked. Akio Kaito, the first author, belonged to Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo 163-8001, Japan. We apologize for the error.

Footnotes

Manuscript source: Unsolicited manuscript

Specialty type: Medicine, research and experimental

Country/Territory of origin: Japan

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Not applicable S-Editor: Zhang L L-Editor: A P-Editor: Xing YX

References
1.  Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. World J Clin Cases. 2019;7:1964-1977.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 30]  [Cited by in F6Publishing: 39]  [Article Influence: 7.8]  [Reference Citation Analysis (1)]